Media ReleasesINOVIQ

View All INOVIQ News


INOVIQ Engages ResearchDX to Develop & Validate SubB2M-Tests


* INOVIQ’s SubB2M technology detects the pan-cancer biomarker Neu5Gc found at elevated levels in multiple human cancers
* SubB2M-based tests are in early development for multiple uses including monitoring of breast and ovarian cancers, and for a general health panel
* ResearchDx, a US-based specialty contract diagnostics organisation, will undertake further development and validation of SubB2M-based tests
* Key milestones met to transfer SubB2M-based tests to an accredited CRO for commercial development and also for a potential LDT laboratory partner in the USA 

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.